Hospitals are thrilled that they’re now able to offer cancer patients pioneering CAR-T treatments, but they’re also running into the omnipresent problem surrounding these and other next-generation therapies: cost.

In a speech Wednesday at the Personalized Medicine Conference, Dr. Betsy Nabel, the president of Brigham and Women’s Hospital, said her hospital and others in the Partners HealthCare system are not being reimbursed fully when they treat patients with CAR-T therapies, leaving the providers to subsidize the treatments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I believe that process cost universities doing the research aproximately 20,000 per patient to regrow the cells outside the body and so the rest of the 400,000 is likely for some patent holder. Therefore I think there’s going to be an industry of sending patients to China for this therapy where they not worried about US patents .

  • Thank you for keeping the public up to date on new research and treatments for cancer. My husband passed away recent look y from Sarcoma. No existing treatments could stop his disease and least of all alleviate his pain. I am still very upset at the Sarcoma center for their lack of communication into clinical trials and innovative therapies to offer patients. Keep up the good work.

  • Wonderful to trade of upcoming new research and new treatment for cancer. Keep up the good work of informing the public of what is in the near future.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy